Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis
CLUES
CLUES (Cognition for Learning and for Understanding Everyday Social Situations): An Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis
2 other identifiers
interventional
58
1 country
1
Brief Summary
The purpose of this study is to test the feasibility of a modification of CET (Cognitive Enhancement Therapy) to address symptomatic and functional difficulties associated with Clinical High Risk for Psychosis (CHR). Cognition for Learning and for Understanding Everyday Social Situations (CLUES) is designed to improve cognitive functioning (e.g., memory, attention, planning, etc.) in order to improve school, work, and social functioning. CLUES includes the following:
- 1.Computerized cognitive remediation ("exercises") to improve cognition.
- 2.Social-cognitive skills group designed to teach participants to act wisely in social situations.
- 3.Individual coaching sessions designed to enhance translation of skills learned from computer exercises and the group into real life.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2015
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2015
CompletedFirst Submitted
Initial submission to the registry
April 14, 2015
CompletedFirst Posted
Study publicly available on registry
June 2, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2019
CompletedMay 7, 2019
May 1, 2019
4 years
April 14, 2015
May 3, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change from Baseline in Social and Role Functioning at 6 Month and 9 Month (clinical interview)
Assessed through clinical interview
Baseline, 6 month, and 9 month
Secondary Outcomes (4)
Change from Baseline in Neurocognitive functioning (neuropsychological test battery)
Baseline, 6 month, and 9 month
Change from Baseline in Social-cognitive functioning (neuropsychological test battery)
Baseline, 6 month, and 9 month
Satisfaction with treatment (Self report of client satisfaction)
6 month and 9 months
Feasibility of treatment (Rates of attendance for all aspects of treatment)
6 months and 9 months
Study Arms (2)
CLUES
EXPERIMENTALactive treatment
therapy and computer games
ACTIVE COMPARATORsupportive therapy + computer games
Interventions
Cognition for learning and for understanding everyday social situations intervention described above
Weekly psychotherapy+ computer games such as sporcle
Eligibility Criteria
You may qualify if:
- Broad criteria for clinical high risk for psychosis including meeting for SIPS clinical high risk syndrome or any two of the following:
- Trait risk: Having a first degree relative with a psychotic disorder, or a schizotypal disorder in the patient
- Positive symptoms: One or more of the attenuated SOPS Positive or Disorganized items scoring mild (3), moderate (4) or severe (5) but not at a psychotic level; these may include one or more Basic Symptoms (Klosterkotter et al 2001).
- Negative symptoms: Two or more of the SOPS negative symptoms rated at least moderate in severity
- Cognition: executive cognitive impairment (at least 1.0 standard deviation deficit relative to age-expected norms on at least 30% of the measures
- Functioning: GAF decline \> 30% over the last 2 years, sustained for \> 1 mo.
You may not qualify if:
- History of meeting full criteria for psychotic disorder
- Significant neurological or medical disorders that may produce cognitive impairment (e.g., seizure disorder, traumatic brain injury)
- More than 6 months (lifetime) of exposure to antipsychotic treatment
- A recent (within the past 3 months) history of substance abuse or dependence
- IQ \< 80
- Failure to achieve at least a 6th grade reading level
- Persistent suicidal or homicidal behavior
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Beth Israel Deaconess Medical Center/ Massachusetts Mental Health Center
Boston, Massachusetts, 02115, United States
Related Publications (34)
Addington J, Cadenhead KS, Cannon TD, Cornblatt B, McGlashan TH, Perkins DO, Seidman LJ, Tsuang M, Walker EF, Woods SW, Heinssen R; North American Prodrome Longitudinal Study. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull. 2007 May;33(3):665-72. doi: 10.1093/schbul/sbl075. Epub 2007 Jan 25.
PMID: 17255119BACKGROUNDBen-Yishay Y, Piasetsky EB, Rattok J. A systematic method for ameliorating disorders in basic attention. In: Meir MJ, Benton AL, Diller L, eds. Neuropsychological Rehabilitation. New York, NY: Guilford; 1985:165 181.
BACKGROUNDBracy OL.PSSCogRehab.Indianapolis, IN: Psychological Software Services Inc; 1994.
BACKGROUNDCannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008 Jan;65(1):28-37. doi: 10.1001/archgenpsychiatry.2007.3.
PMID: 18180426BACKGROUNDCannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8(3):470-84. doi: 10.1093/schbul/8.3.470.
PMID: 7134891BACKGROUNDCarrion RE, McLaughlin D, Goldberg TE, Auther AM, Olsen RH, Olvet DM, Correll CU, Cornblatt BA. Prediction of functional outcome in individuals at clinical high risk for psychosis. JAMA Psychiatry. 2013 Nov;70(11):1133-42. doi: 10.1001/jamapsychiatry.2013.1909.
PMID: 24006090BACKGROUNDEack SM, Greenwald DP, Hogarty SS, Cooley SJ, DiBarry AL, Montrose DM, Keshavan MS. Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatr Serv. 2009 Nov;60(11):1468-76. doi: 10.1176/appi.ps.60.11.1468.
PMID: 19880464BACKGROUNDEack SM, Hogarty GE, Greenwald DP, Hogarty SS, Keshavan MS. Cognitive enhancement therapy improves emotional intelligence in early course schizophrenia: preliminary effects. Schizophr Res. 2007 Jan;89(1-3):308-11. doi: 10.1016/j.schres.2006.08.018. Epub 2006 Oct 19.
PMID: 17055227BACKGROUNDEack SM, Hogarty GE, Cho RY, Prasad KM, Greenwald DP, Hogarty SS, Keshavan MS. Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial. Arch Gen Psychiatry. 2010 Jul;67(7):674-82. doi: 10.1001/archgenpsychiatry.2010.63. Epub 2010 May 3.
PMID: 20439824BACKGROUNDEack SM, Greeno CG, Pogue-Geile MF, Newhill CE, Hogarty GE, Keshavan MS. Assessing social-cognitive deficits in schizophrenia with the Mayer-Salovey-Caruso Emotional Intelligence Test. Schizophr Bull. 2010 Mar;36(2):370-80. doi: 10.1093/schbul/sbn091. Epub 2008 Jul 22.
PMID: 18648021BACKGROUNDEack SM, Greenwald DP, Hogarty SS, Keshavan MS. One-year durability of the effects of cognitive enhancement therapy on functional outcome in early schizophrenia. Schizophr Res. 2010 Jul;120(1-3):210-6. doi: 10.1016/j.schres.2010.03.042. Epub 2010 May 15.
PMID: 20472402BACKGROUNDEack SM, Hogarty GE, Greenwald DP, Hogarty SS, Keshavan MS. Effects of Cognitive Enhancement Therapy on Employment Outcomes in Early Schizophrenia: Results From a Two-Year Randomized Trial. Res Soc Work Pract. 2011 Jan 27;21(1):32-42. doi: 10.1177/1049731509355812.
PMID: 23885163BACKGROUNDFisher M, Loewy R, Hardy K, Schlosser D, Vinogradov S. Cognitive interventions targeting brain plasticity in the prodromal and early phases of schizophrenia. Annu Rev Clin Psychol. 2013;9:435-63. doi: 10.1146/annurev-clinpsy-032511-143134. Epub 2013 Jan 7.
PMID: 23297786BACKGROUNDFusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultze-Lutter F, Keshavan M, Wood S, Ruhrmann S, Seidman LJ, Valmaggia L, Cannon T, Velthorst E, De Haan L, Cornblatt B, Bonoldi I, Birchwood M, McGlashan T, Carpenter W, McGorry P, Klosterkotter J, McGuire P, Yung A. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2013 Jan;70(1):107-20. doi: 10.1001/jamapsychiatry.2013.269.
PMID: 23165428BACKGROUNDGiuliano AJ, Li H, Mesholam-Gately RI, Sorenson SM, Woodberry KA, Seidman LJ. Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review. Curr Pharm Des. 2012;18(4):399-415. doi: 10.2174/138161212799316019.
PMID: 22239571BACKGROUNDGreen MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull. 2000;26(1):119-36. doi: 10.1093/oxfordjournals.schbul.a033430.
PMID: 10755673BACKGROUNDGreen MF, Hellemann G, Horan WP, Lee J, Wynn JK. From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. Arch Gen Psychiatry. 2012 Dec;69(12):1216-24. doi: 10.1001/archgenpsychiatry.2012.652.
PMID: 23026889BACKGROUNDHeinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998 Jul;12(3):426-45. doi: 10.1037//0894-4105.12.3.426.
PMID: 9673998BACKGROUNDHogarty GE, Flesher S, Ulrich R, Carter M, Greenwald D, Pogue-Geile M, Kechavan M, Cooley S, DiBarry AL, Garrett A, Parepally H, Zoretich R. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry. 2004 Sep;61(9):866-76. doi: 10.1001/archpsyc.61.9.866.
PMID: 15351765BACKGROUNDHogarty, G. E., & Greenwald, D. P: Cognitive Enhancement Therapy: The Training Manual. University of Pittsburgh Medical Center: Authors. Available through www.CognitiveEnhancementTherapy.com, 2006.
BACKGROUNDKeshavan MS, DeLisi LE, Seidman LJ. Early and broadly defined psychosis risk mental states. Schizophr Res. 2011 Mar;126(1-3):1-10. doi: 10.1016/j.schres.2010.10.006. Epub 2010 Nov 30.
PMID: 21123033BACKGROUNDKeshavan MS, Hogarty GE. Brain maturational processes and delayed onset in schizophrenia. Dev Psychopathol. 1999 Summer;11(3):525-43. doi: 10.1017/s0954579499002199.
PMID: 10532623BACKGROUNDKohler CG, Turner TH, Bilker WB, Brensinger CM, Siegel SJ, Kanes SJ, Gur RE, Gur RC. Facial emotion recognition in schizophrenia: intensity effects and error pattern. Am J Psychiatry. 2003 Oct;160(10):1768-74. doi: 10.1176/appi.ajp.160.10.1768.
PMID: 14514489BACKGROUNDMayer JD, Salovey P, Caruso DR, Sitarenios G. Measuring emotional intelligence with the MSCEIT V2.0. Emotion. 2003 Mar;3(1):97-105. doi: 10.1037/1528-3542.3.1.97.
PMID: 12899321BACKGROUNDMcDonald S, Bornhofen C, Shum D, Long E, Saunders C, Neulinger K. Reliability and validity of The Awareness of Social Inference Test (TASIT): a clinical test of social perception. Disabil Rehabil. 2006 Dec 30;28(24):1529-42. doi: 10.1080/09638280600646185.
PMID: 17178616BACKGROUNDMcGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002 Oct;59(10):921-8. doi: 10.1001/archpsyc.59.10.921.
PMID: 12365879BACKGROUNDMesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology. 2009 May;23(3):315-36. doi: 10.1037/a0014708.
PMID: 19413446BACKGROUNDNuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004 Dec 15;72(1):29-39. doi: 10.1016/j.schres.2004.09.007.
PMID: 15531405BACKGROUNDNuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008 Feb;165(2):203-13. doi: 10.1176/appi.ajp.2007.07010042. Epub 2008 Jan 2.
PMID: 18172019BACKGROUNDWaber DP, Holmes JM. Assessing children's copy productions of the Rey-Osterrieth Complex Figure. J Clin Exp Neuropsychol. 1985 Jun;7(3):264-80. doi: 10.1080/01688638508401259.
PMID: 3998091BACKGROUNDWood SJ, Yung AR, McGorry PD, Pantelis C. Neuroimaging and treatment evidence for clinical staging in psychotic disorders: from the at-risk mental state to chronic schizophrenia. Biol Psychiatry. 2011 Oct 1;70(7):619-25. doi: 10.1016/j.biopsych.2011.05.034. Epub 2011 Jul 18.
PMID: 21762875BACKGROUNDWoodberry KA, Giuliano AJ, Seidman LJ. Premorbid IQ in schizophrenia: a meta-analytic review. Am J Psychiatry. 2008 May;165(5):579-87. doi: 10.1176/appi.ajp.2008.07081242. Epub 2008 Apr 15.
PMID: 18413704BACKGROUNDVinogradov S, Fisher M, de Villers-Sidani E. Cognitive training for impaired neural systems in neuropsychiatric illness. Neuropsychopharmacology. 2012 Jan;37(1):43-76. doi: 10.1038/npp.2011.251. Epub 2011 Nov 2.
PMID: 22048465BACKGROUNDWykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011 May;168(5):472-85. doi: 10.1176/appi.ajp.2010.10060855. Epub 2011 Mar 15.
PMID: 21406461BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Matcheri Keshavan, MD
Beth Israel Deaconess Medical Center/ Massachusetts Mental Health Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Stanley Cobb Professor of Psychiatry
Study Record Dates
First Submitted
April 14, 2015
First Posted
June 2, 2015
Study Start
January 1, 2015
Primary Completion
January 1, 2019
Study Completion
January 1, 2019
Last Updated
May 7, 2019
Record last verified: 2019-05